BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38060494)

  • 1. Identification of protein signatures for lung cancer subtypes based on BPSO method.
    Wang J; Wang H; Xu J; Song Q; Zhou B; Shangguan J; Xue M; Wang Y
    PLoS One; 2023; 18(12):e0294243. PubMed ID: 38060494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods.
    Chen JW; Dhahbi J
    Sci Rep; 2021 Jun; 11(1):13323. PubMed ID: 34172784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
    Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
    BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
    Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
    Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
    Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
    BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
    Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
    Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
    [No Abstract]   [Full Text] [Related]  

  • 9. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
    BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
    Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
    Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using feature selection and Bayesian network identify cancer subtypes based on proteomic data.
    Wang Y; Gao X; Ru X; Sun P; Wang J
    J Proteomics; 2023 May; 280():104895. PubMed ID: 37024076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of prognostic biomarkers in lung adenocarcinoma based on aberrant lncRNA-miRNA-mRNA networks and Cox regression models.
    Yao Y; Zhang T; Qi L; Liu R; Liu G; Wang J; Song Q; Sun C
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31950990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The High Expression of PTPRH Is Associated with Poor Prognosis of Human Lung Adenocarcinoma.
    Chen A; Ding S; Shen X; Lin X
    Comput Math Methods Med; 2021; 2021():9932088. PubMed ID: 34367321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative bioinformatics analysis the clinical value of KMT5A in different subtypes of lung cancer.
    Liu S; Tian W; Li B
    Comput Biol Chem; 2022 Feb; 96():107603. PubMed ID: 34894606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
    Jiang H; Xu S; Chen C
    BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.